An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Biphenyl compounds are organic substances consisting of two phenyl rings connected by a single covalent bond, and can exhibit various properties and uses, including as intermediates in chemical synthesis, components in plastics and dyes, and as additives in fuels.
An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
Tetrazoles are heterocyclic organic compounds containing a 1,3,5-triazole ring with an additional nitrogen atom, often used in pharmaceuticals as bioisosteres for carboxylic acid groups due to their isoelectronic nature and similar hydrogen bonding capabilities.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
An angiotensin receptor subtype that is expressed at high levels in fetal tissues. Many effects of the angiotensin type 2 receptor such as VASODILATION and sodium loss are the opposite of that of the ANGIOTENSIN TYPE 1 RECEPTOR.
Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells.
An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
Agents that antagonize the ANGIOTENSIN II TYPE 2 RECEPTOR.
A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.
A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
Oligopeptides which are important in the regulation of blood pressure (VASOCONSTRICTION) and fluid homeostasis via the RENIN-ANGIOTENSIN SYSTEM. These include angiotensins derived naturally from precursor ANGIOTENSINOGEN, and those synthesized.
An ANGIOTENSIN II analog which acts as a highly specific inhibitor of ANGIOTENSIN TYPE 1 RECEPTOR.
Drugs used to cause constriction of the blood vessels.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Compounds with a BENZENE fused to IMIDAZOLES.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992) EC 3.4.15.1.

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. (1/1572)

BACKGROUND: Incomplete suppression of the renin-angiotensin system during long-term ACE inhibition may contribute to symptomatic deterioration in patients with severe congestive heart failure (CHF). Combined angiotensin II type I (AT1) receptor blockade and ACE inhibition more completely suppresses the activated renin-angiotensin system than either intervention alone in sodium-depleted normal individuals. Whether AT1 receptor blockade with losartan improves exercise capacity in patients with severe CHF already treated with ACE inhibitors is unknown. METHODS AND RESULTS: Thirty-three patients with severe CHF despite treatment with maximally recommended or tolerated doses of ACE inhibitors were randomized 1:1 to receive 50 mg/d losartan or placebo for 6 months in addition to standard therapy in a multicenter, double-blind trial. Peak aerobic capacity (V(O2)) during symptom-limited treadmill exercise and NYHA functional class were determined at baseline and after 3 and 6 months of double-blind therapy. Peak V(O2) at baseline and after 3 and 6 months were 13.5+/-0.6, 15.1+/-1.0, and 15.7+/-1.1 mL. kg-1. min-1, respectively, in patients receiving losartan and 14.1+/-0.6, 14.3+/-0.9, and 13.6+/-1.1 mL. kg-1. min-1, respectively, in patients receiving placebo (P<0.02 for treatment group-by-time interaction). Functional class improved by at least one NYHA class in 9 of 16 patients receiving losartan and 1 of 17 patients receiving placebo. CONCLUSIONS: Losartan enhances peak exercise capacity and alleviates symptoms in patients with CHF who are severely symptomatic despite treatment with maximally recommended or tolerated doses of ACE inhibitors.  (+info)

Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease? (2/1572)

At the present time we cannot assume that the proven benefits of ACEI on renal disease will be reproduced by using AT1-ra. With potentially differing modes of activity of these drugs, they cannot be seen as interchangeable and ACEI should remain the drug of choice in patients with progressive renal disease unless they are not tolerated. It is possible that AT1-ra may offer additional advantages in some patients or that synergy exists between the two agents, but this view will remain entirely speculative unless proper trials are conducted. Despite the results of the ELITE study [22], the uncertainty regarding the use AT1-ra in cardiovascular disease mirrors that of renal disease. This issue is obviously of relevance to the nephrologist in view of the spectrum of cardiac disease that accompanies chronic renal failure, such as left ventricular hypertrophy and cardiac failure, which provide multiple indications for manipulation of RAS. Despite their renoprotective effect, previous studies on ACEI [3,4] have not shown an overall reduction in mortality and this issue needs to be addressed in addition to renoprotection in studies comparing AT1-ra and ACEI.  (+info)

Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. (3/1572)

The mechanisms by which sympathetic function is augmented in chronic heart failure (CHF) are not well understood. A previous study from this laboratory (Circ Res. 1998;82:496-502) indicated that blockade of nitric oxide (NO) synthesis resulted in only an increase in renal sympathetic nerve activity (RSNA) when plasma angiotensin II (Ang II) levels were elevated. The present study was undertaken to determine if NO reduces RSNA in rabbits with CHF when Ang II receptors are blocked. Twenty-four New Zealand White rabbits were instrumented with cardiac dimension crystals, a left ventricular pacing lead, and a pacemaker. After pacing at 360 to 380 bpm for approximately 3 weeks, a renal sympathetic nerve electrode and arterial and venous catheters were implanted. Studies were carried out in the conscious state 3 to 7 days after electrode implantation. The effects of a 1-hour infusion of sodium nitroprusside (SNP; 3 microgram . kg-1. min-1) on RSNA and mean arterial pressure (MAP) were determined before and after Ang II blockade with losartan (5 mg/kg) in normal and CHF rabbits. Changes in MAP were readjusted to normal with phenylephrine. Before losartan, SNP evoked a decrease in MAP and an increase in RSNA in both groups that was baroreflex-mediated, because both MAP and RSNA returned to control when phenylephrine was administered. In the normal group, losartan plus SNP caused a reduction in MAP and an increase in RSNA that was 152.6+/-9.8% of control. Phenylephrine returned both MAP and RSNA back to the control levels. However, in the CHF group, losartan plus SNP evoked a smaller change in RSNA for equivalent changes in MAP (117.1+/-4.1% of control). On returning MAP to the control level with phenylephrine, RSNA was reduced to 65.2+/-2.9% of control (P<0. 0001). These data suggest that endogenous Ang II contributes to the sympathoexcitation in the CHF state and that blockade of Ang II receptors plus providing an exogenous source of NO reduces RSNA below the elevated baseline levels. We conclude that both a loss of NO and an increase in Ang II are necessary for sustained increases in sympathetic nerve activity in the CHF state.  (+info)

Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. (4/1572)

Angiotensin II type 1 (AT1) receptor blockade attenuates myocardial fibrosis after myocardial infarction (MI). However, whether inhibition of fibrosis by AT1 receptor blockade influences myocardial stiffness and contractility is unknown. We measured left ventricular (LV) hemodynamics, papillary muscle function, and myocardial stiffness and fibrosis in rats randomized to losartan or placebo 1 day after MI and treated subsequently for 8 wk. Losartan decreased LV and right ventricular weights as well as mean aortic and LV systolic pressures in sham and MI rats. LV end-diastolic pressure increased after MI and was decreased with losartan. Maximal developed tension and peak rate of tension rise and decline were decreased in MI vs. sham rats. Interstitial fibrosis developed after MI and was prevented in losartan-treated MI rats. The development of abnormal myocardial stiffness after MI was prevented by losartan. After MI, AT1 receptor blockade prevents an abnormal increase in myocardial collagen content. This effect was associated with a normalization of passive myocardial stiffness.  (+info)

Maintenance of blood pressure in normotensive dogs by endothelin. (5/1572)

The role of endothelin (ET)-1 in blood pressure homeostasis and the interaction with the renin-angiotensin system (RAS) was investigated in normotensive conscious dogs. ETA receptors were blocked by LU-135252 (1-30 mg/kg); trandolapril (2 mg/kg) or losartan (10 mg/kg) was used to inhibit the RAS. LU-135252 in oral doses of 3-30 mg/kg significantly reduced mean arterial pressure (MAP) by approximately 10 mmHg maximally, whereas trandolapril or losartan were without any effect. MAP reduction was more pronounced when LU-135252 was combined with either losartan (-15.5 +/- 3.2 mmHg; 2 h postadministration; P < 0.05) or trandolapril (-30.9 +/- 3.6 mmHg; P < 0.05). When endogenous nitric oxide (NO) generation was blocked but NO concomitantly infused, this synergistic effect on MAP was prevented. The data show that ET-1 contributes to the maintenance of blood pressure via ETA receptors. Furthermore, ET-1 and ANG II play a prominent role in the control of blood pressure by opposing the effects of NO. The pronounced blood pressure fall after combined blockade of ETA receptors and the RAS may be mediated by an enhanced release of NO.  (+info)

Renal and hemodynamic effects of losartan in conscious dogs during controlled mechanical ventilation. (6/1572)

In 12 conscious dogs, we investigated whether the angiotensin II-receptor antagonist losartan increases renal sodium excretion and urine volume during controlled mechanical ventilation (CMV) with positive end-expiratory pressure. In four experimental protocols, the dogs were extracellular volume (ECV) expanded (electrolyte solution, 0.5 ml. kg-1. min-1 iv) or not and received losartan (100 micrograms. kg-1. min-1 iv) or not. They breathed spontaneously during the 1st and 4th hour and received CMV with positive end-expiratory pressure (mean airway pressure 20 cmH2O) during the 2nd and 3rd hours. In the expansion group, dogs with losartan excreted approximately 18% more sodium (69 +/- 7 vs. 38 +/- 5 micromol. min-1. kg-1) and 15% more urine during the 2 h of CMV because of a higher glomerular filtration rate (5.3 +/- 0.3 vs. 4.5 +/- 0.2 ml. min-1. kg-1) and the tubular effects of losartan. In the group without expansion, sodium excretion (2.0 +/- 0.6 vs. 2.6 +/- 1.0 micromol. min-1. kg-1) and glomerular filtration rate (3.8 +/- 0.3 vs. 3.8 +/- 0.4 ml. min-1. kg-1) did not change, and urine volume decreased similarly in both groups during CMV. Plasma vasopressin and aldosterone increased in both groups, and plasma renin activity increased from 4.9 +/- 0.7 to 7.8 +/- 1.3 ng ANG I. ml-1. h-1 during CMV in nonexpanded dogs without losartan. Mean arterial pressure decreased by 10 mmHg in nonexpanded dogs with losartan. In conclusion, losartan increases sodium excretion and urine volume during CMV if the ECV is expanded. If the ECV is not expanded, a decrease in mean arterial blood pressure and/or an increase in aldosterone and vasopressin during CMV attenuates the renal effects of losartan.  (+info)

Inhibition of beta-myosin heavy chain gene expression in pressure overload rat heart by losartan and captopril. (7/1572)

AIM: To study the effects of losartan and captopril on beta-myosin heavy chain (MHC), and alpha-MHC gene expression. METHODS: Pressure overload was produced by abdominal aortic coarctation (AAC) in rats. alpha- and beta-MHC mRNA were measured by Northern blot. RESULTS: In left ventricular myocardium of sham-operated rats, the alpha-MHC mRNA predominated, while the beta-MHC mRNA was only detectable. In response AAC, there was a 70-fold increase in the beta-MHC mRNA (P < 0.01), while alpha-MHC mRNA reduced to 26% (P < 0.01). Losartan (3 mg.kg-1.d-1, i.g. for 11 d) to AAC rats caused inhibitions of beta-MHC by 96% and alpha-MHC by 86% gene expression without lowering blood pressure. A reduction in beta-MHC mRNA was also seen in captopril-treated rats (30 mg.kg-1.d-1, i.g. for 11 d), but the inhibitory effect of captopril on alpha-MHC mRNA was less than that of losartan (44% vs 86%, P < 0.05). CONCLUSIONS: The shift of MHC isoform induced by pressure overload is due to up-regulation of beta-MHC and down-regulation of alpha-MHC gene expression. Inhibition of beta-MHC gene expression by losartan is achieved primarily by direct blockade of angiotensin II type I receptors in the myocardium, independent on hemodynamics.  (+info)

Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV. (8/1572)

In this study, a nitric oxide (NO) sensor was used to examine the ability of angiotensin II (AngII), AngIV, and bradykinin (Bk) to stimulate NO release from porcine pulmonary artery (PPAE) and porcine aortic endothelial (PAE) cells and to explore the mechanism of the AngII-stimulated NO release. Physiologic concentrations of AngII, but not Bk, caused release of NO from PPAE cells. In contrast, Bk, but not AngII, stimulated NO release from PAE cells. AngIII-stimulated NO release from PPAE cells required extracellular L-arginine and was inhibited by L-nitro-arginine methyl ester. AT1 and AT2 receptor inhibition had no affect on AngII-mediated NO release or activation of NO synthase (NOS). AngIV, an AngII metabolite with binding sites that are pharmacologically distinct from the classic AngII receptors, stimulated considerably greater NO release and greater endothelial-type constitutive NOS activity than the same amount of AngII. The AngIV receptor antagonist, divalinal AngIV, blocked both AngII- and AngIV-mediated NO release as well as NOS activation. The results demonstrate that AngIV and the AngIV receptor are responsible, at least in part, for AngII-stimulated NO release and the associated endothelium-dependent vasorelaxation. Furthermore, these results suggest that differences exist in both AngII- and Bk-mediated NO release between PPAE and PAE cells, which may reflect important differences in response to these hormones between vascular beds.  (+info)

Losartan is an angiotensin II receptor blocker (ARB) medication that is primarily used to treat hypertension (high blood pressure), but can also be used to manage chronic heart failure and protect against kidney damage in patients with type 2 diabetes. It works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow and blood pressure to rise. By blocking this hormone's effects, losartan helps relax and widen blood vessels, making it easier for the heart to pump blood and reducing the workload on the cardiovascular system.

The medical definition of losartan is: "A synthetic angiotensin II receptor antagonist used in the treatment of hypertension, chronic heart failure, and diabetic nephropathy. It selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation, decreased aldosterone secretion, and increased renin activity."

Angiotensin receptor antagonists (ARAs), also known as angiotensin II receptor blockers (ARBs), are a class of medications used to treat hypertension, heart failure, and protect against kidney damage in patients with diabetes. They work by blocking the action of angiotensin II, a potent vasoconstrictor and hormone that increases blood pressure and promotes tissue fibrosis. By blocking the binding of angiotensin II to its receptors, ARAs cause relaxation of blood vessels, decreased sodium and water retention, and reduced cardiac remodeling, ultimately leading to improved cardiovascular function and reduced risk of organ damage. Examples of ARAs include losartan, valsartan, irbesartan, and candesartan.

Angiotensin II Type 1 Receptor Blockers (ARBs) are a class of medications used to treat hypertension, heart failure, and protect against kidney damage in patients with diabetes. They work by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict and blood pressure to increase, at its type 1 receptor. By blocking this effect, ARBs cause blood vessels to dilate, reducing blood pressure and decreasing the workload on the heart. Examples of ARBs include losartan, valsartan, irbesartan, and candesartan.

Antihypertensive agents are a class of medications used to treat high blood pressure (hypertension). They work by reducing the force and rate of heart contractions, dilating blood vessels, or altering neurohormonal activation to lower blood pressure. Examples include diuretics, beta blockers, ACE inhibitors, ARBs, calcium channel blockers, and direct vasodilators. These medications may be used alone or in combination to achieve optimal blood pressure control.

Biphenyl compounds, also known as diphenyls, are a class of organic compounds consisting of two benzene rings linked by a single carbon-carbon bond. The chemical structure of biphenyl compounds can be represented as C6H5-C6H5. These compounds are widely used in the industrial sector, including as intermediates in the synthesis of other chemicals, as solvents, and in the production of plastics and dyes. Some biphenyl compounds also have biological activity and can be found in natural products. For example, some plant-derived compounds that belong to this class have been shown to have anti-inflammatory, antioxidant, and anticancer properties.

The Angiotensin II Receptor Type 1 (AT1 receptor) is a type of G protein-coupled receptor that binds and responds to the hormone angiotensin II, which plays a crucial role in the renin-angiotensin-aldosterone system (RAAS). The RAAS is a vital physiological mechanism that regulates blood pressure, fluid, and electrolyte balance.

The AT1 receptor is found in various tissues throughout the body, including the vascular smooth muscle cells, cardiac myocytes, adrenal glands, kidneys, and brain. When angiotensin II binds to the AT1 receptor, it activates a series of intracellular signaling pathways that lead to vasoconstriction, increased sodium and water reabsorption in the kidneys, and stimulation of aldosterone release from the adrenal glands. These effects ultimately result in an increase in blood pressure and fluid volume.

AT1 receptor antagonists, also known as angiotensin II receptor blockers (ARBs), are a class of drugs used to treat hypertension, heart failure, and other cardiovascular conditions. By blocking the AT1 receptor, these medications prevent angiotensin II from exerting its effects on the cardiovascular system, leading to vasodilation, decreased sodium and water reabsorption in the kidneys, and reduced aldosterone release. These actions ultimately result in a decrease in blood pressure and fluid volume.

Angiotensin II is a potent vasoactive peptide hormone that plays a critical role in the renin-angiotensin-aldosterone system (RAAS), which is a crucial regulator of blood pressure and fluid balance in the body. It is formed from angiotensin I through the action of an enzyme called angiotensin-converting enzyme (ACE).

Angiotensin II has several physiological effects on various organs, including:

1. Vasoconstriction: Angiotensin II causes contraction of vascular smooth muscle, leading to an increase in peripheral vascular resistance and blood pressure.
2. Aldosterone release: Angiotensin II stimulates the adrenal glands to release aldosterone, a hormone that promotes sodium reabsorption and potassium excretion in the kidneys, thereby increasing water retention and blood volume.
3. Sympathetic nervous system activation: Angiotensin II activates the sympathetic nervous system, leading to increased heart rate and contractility, further contributing to an increase in blood pressure.
4. Thirst regulation: Angiotensin II stimulates the hypothalamus to increase thirst, promoting water intake and helping to maintain intravascular volume.
5. Cell growth and fibrosis: Angiotensin II has been implicated in various pathological processes, such as cell growth, proliferation, and fibrosis, which can contribute to the development of cardiovascular and renal diseases.

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two classes of medications commonly used in clinical practice to target the RAAS by blocking the formation or action of angiotensin II, respectively. These drugs have been shown to be effective in managing hypertension, heart failure, and chronic kidney disease.

Tetrazoles are a class of heterocyclic aromatic organic compounds that contain a five-membered ring with four nitrogen atoms and one carbon atom. They have the chemical formula of C2H2N4. Tetrazoles are stable under normal conditions, but can decompose explosively when heated or subjected to strong shock.

In the context of medicinal chemistry, tetrazoles are sometimes used as bioisosteres for carboxylic acids, as they can mimic some of their chemical and biological properties. This has led to the development of several drugs that contain tetrazole rings, such as the antiviral drug tenofovir and the anti-inflammatory drug celecoxib.

However, it's important to note that 'tetrazoles' is not a medical term per se, but rather a chemical term that can be used in the context of medicinal chemistry or pharmacology.

Imidazoles are a class of heterocyclic organic compounds that contain a double-bonded nitrogen atom and two additional nitrogen atoms in the ring. They have the chemical formula C3H4N2. In a medical context, imidazoles are commonly used as antifungal agents. Some examples of imidazole-derived antifungals include clotrimazole, miconazole, and ketoconazole. These medications work by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, leading to increased permeability and death of the fungal cells. Imidazoles may also have anti-inflammatory, antibacterial, and anticancer properties.

The Angiotensin II Receptor Type 2 (AT2R) is a type of G protein-coupled receptor that binds to the hormone angiotensin II, which plays a crucial role in the renin-angiotensin system (RAS), a vital component in regulating blood pressure and fluid balance.

The AT2R is expressed in various tissues, including the heart, blood vessels, kidneys, brain, and reproductive organs. When angiotensin II binds to the AT2R, it initiates several signaling pathways that can lead to vasodilation, anti-proliferation, anti-inflammation, and neuroprotection.

In contrast to the Angiotensin II Receptor Type 1 (AT1R), which is primarily associated with vasoconstriction, sodium retention, and fibrosis, AT2R activation has been shown to have protective effects in several pathological conditions, including hypertension, heart failure, atherosclerosis, and kidney disease.

However, the precise functions of AT2R are still being investigated, and its role in various physiological and pathophysiological processes may vary depending on the tissue type and context.

Angiotensin receptors are a type of G protein-coupled receptor that binds the angiotensin peptides, which are important components of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a hormonal system that regulates blood pressure and fluid balance.

There are two main types of angiotensin receptors: AT1 and AT2. Activation of AT1 receptors leads to vasoconstriction, increased sodium and water reabsorption in the kidneys, and cell growth and proliferation. On the other hand, activation of AT2 receptors has opposite effects, such as vasodilation, natriuresis (increased excretion of sodium in urine), and anti-proliferative actions.

Angiotensin II is a potent activator of AT1 receptors, while angiotensin IV has high affinity for AT2 receptors. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are two classes of drugs that target the RAAS by blocking the formation or action of angiotensin II, leading to decreased activation of AT1 receptors and improved cardiovascular outcomes.

Enalapril is a medication that belongs to a class of drugs called angiotensin-converting enzyme (ACE) inhibitors. It works by blocking the action of a hormone in the body called angiotensin II, which causes blood vessels to narrow and tighten. By blocking this hormone, Enalapril helps relax and widen blood vessels, making it easier for the heart to pump blood and reducing the workload on the heart.

Enalapril is commonly used to treat high blood pressure (hypertension), congestive heart failure, and to improve survival after a heart attack. It may also be used to treat other conditions as determined by your doctor.

The medication comes in the form of tablets or capsules that are taken orally, usually once or twice a day with or without food. The dosage will depend on various factors such as the patient's age, weight, and medical condition. It is important to follow the instructions of your healthcare provider when taking Enalapril.

Like all medications, Enalapril can cause side effects, including dry cough, dizziness, headache, fatigue, and nausea. More serious side effects may include allergic reactions, kidney problems, and low blood pressure. If you experience any concerning symptoms while taking Enalapril, it is important to contact your healthcare provider right away.

Angiotensin-Converting Enzyme (ACE) inhibitors are a class of medications that are commonly used to treat various cardiovascular conditions, such as hypertension (high blood pressure), heart failure, and diabetic nephropathy (kidney damage in people with diabetes).

ACE inhibitors work by blocking the action of angiotensin-converting enzyme, an enzyme that converts the hormone angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor, meaning it narrows blood vessels and increases blood pressure. By inhibiting the conversion of angiotensin I to angiotensin II, ACE inhibitors cause blood vessels to relax and widen, which lowers blood pressure and reduces the workload on the heart.

Some examples of ACE inhibitors include captopril, enalapril, lisinopril, ramipril, and fosinopril. These medications are generally well-tolerated, but they can cause side effects such as cough, dizziness, headache, and elevated potassium levels in the blood. It is important for patients to follow their healthcare provider's instructions carefully when taking ACE inhibitors and to report any unusual symptoms or side effects promptly.

The Renin-Angiotensin System (RAS) is a complex hormonal system that regulates blood pressure, fluid and electrolyte balance, and vascular resistance. It plays a crucial role in the pathophysiology of hypertension, heart failure, and kidney diseases.

Here's a brief overview of how it works:

1. Renin is an enzyme that is released by the juxtaglomerular cells in the kidneys in response to decreased blood pressure or reduced salt delivery to the distal tubules.
2. Renin acts on a protein called angiotensinogen, which is produced by the liver, converting it into angiotensin I.
3. Angiotensin-converting enzyme (ACE), found in the lungs and other tissues, then converts angiotensin I into angiotensin II, a potent vasoconstrictor that narrows blood vessels and increases blood pressure.
4. Angiotensin II also stimulates the release of aldosterone from the adrenal glands, which promotes sodium and water reabsorption in the kidneys, further increasing blood volume and blood pressure.
5. Additionally, angiotensin II has direct effects on the heart, promoting hypertrophy and remodeling, which can contribute to heart failure.
6. The RAS can be modulated by various medications, such as ACE inhibitors, angiotensin receptor blockers (ARBs), and aldosterone antagonists, which are commonly used to treat hypertension, heart failure, and kidney diseases.

Blood pressure is the force exerted by circulating blood on the walls of the blood vessels. It is measured in millimeters of mercury (mmHg) and is given as two figures:

1. Systolic pressure: This is the pressure when the heart pushes blood out into the arteries.
2. Diastolic pressure: This is the pressure when the heart rests between beats, allowing it to fill with blood.

Normal blood pressure for adults is typically around 120/80 mmHg, although this can vary slightly depending on age, sex, and other factors. High blood pressure (hypertension) is generally considered to be a reading of 130/80 mmHg or higher, while low blood pressure (hypotension) is usually defined as a reading below 90/60 mmHg. It's important to note that blood pressure can fluctuate throughout the day and may be affected by factors such as stress, physical activity, and medication use.

Hypertension is a medical term used to describe abnormally high blood pressure in the arteries, often defined as consistently having systolic blood pressure (the top number in a blood pressure reading) over 130 mmHg and/or diastolic blood pressure (the bottom number) over 80 mmHg. It is also commonly referred to as high blood pressure.

Hypertension can be classified into two types: primary or essential hypertension, which has no identifiable cause and accounts for about 95% of cases, and secondary hypertension, which is caused by underlying medical conditions such as kidney disease, hormonal disorders, or use of certain medications.

If left untreated, hypertension can lead to serious health complications such as heart attack, stroke, heart failure, and chronic kidney disease. Therefore, it is important for individuals with hypertension to manage their condition through lifestyle modifications (such as healthy diet, regular exercise, stress management) and medication if necessary, under the guidance of a healthcare professional.

Angiotensin I is a decapeptide (a peptide consisting of ten amino acids) that is generated by the action of an enzyme called renin on a protein called angiotensinogen. Renin cleaves angiotensinogen to produce angiotensin I, which is then converted to angiotensin II by the action of an enzyme called angiotensin-converting enzyme (ACE).

Angiotensin II is a potent vasoconstrictor, meaning it causes blood vessels to narrow and blood pressure to increase. It also stimulates the release of aldosterone from the adrenal glands, which leads to increased sodium and water reabsorption in the kidneys, further increasing blood volume and blood pressure.

Angiotensin I itself has little biological activity, but it is an important precursor to angiotensin II, which plays a key role in regulating blood pressure and fluid balance in the body.

Hydrochlorothiazide is a diuretic drug, which means it helps the body get rid of extra salt and water by increasing the amount of urine that is produced. The medical definition of Hydrochlorothiazide is:

A thiazide diuretic drug used to treat hypertension and edema associated with heart failure, liver cirrhosis, and kidney disorders. It works by inhibiting the reabsorption of sodium and chloride ions in the distal convoluted tubule of the nephron, which increases water excretion and decreases blood volume and pressure. Hydrochlorothiazide may be used alone or in combination with other antihypertensive agents. It is also used to treat conditions such as diabetes insipidus, renal tubular acidosis, and hypercalcemia.

The usual starting dose of hydrochlorothiazide for adults is 25 mg to 50 mg once a day, which may be increased gradually depending on the patient's response. The maximum recommended daily dose is 100 mg. Common side effects of hydrochlorothiazide include increased urination, headache, dizziness, and muscle cramps.

Angiotensin II Type 2 Receptor Blockers (AT2RBs) are a class of drugs that selectively block the activation of Angiotensin II Type 2 receptors (AT2R). These receptors are found in various tissues throughout the body and play a role in regulating blood pressure, inflammation, and cell growth.

Angiotensin II is a hormone that constricts blood vessels and increases blood pressure. It binds to both AT1R and AT2R, but its effects are mainly mediated through AT1R. AT2RBs work by blocking the action of Angiotensin II at the AT2R, which can help lower blood pressure and reduce inflammation.

AT2RBs have been shown to have potential benefits in various clinical settings, including heart failure, diabetes, and kidney disease. However, their use is not as widespread as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which primarily target the AT1R.

Some examples of AT2RBs include EMA401, PD123319, and TRV120027.

Amlodipine is a type of medication known as a calcium channel blocker, which is primarily used to treat high blood pressure and angina (chest pain caused by reduced blood flow to the heart). It works by relaxing the muscles around the blood vessels, which causes them to widen and improves blood flow. This helps to lower blood pressure and reduce the workload on the heart, making it easier for the heart to pump blood effectively.

Amlodipine is available in various strengths as a tablet or an extended-release tablet, and it is typically taken once daily. The medication may take several weeks to reach its full effect, so it is important to continue taking it even if you do not notice any immediate improvement in your symptoms.

As with any medication, amlodipine can cause side effects, including headache, dizziness, fatigue, and swelling of the ankles or feet. In rare cases, it may also cause more serious side effects such as allergic reactions, irregular heartbeat, or liver damage. If you experience any unusual symptoms while taking amlodipine, it is important to contact your healthcare provider right away.

It is important to follow your healthcare provider's instructions carefully when taking amlodipine, and to inform them of any other medications or supplements that you are taking, as well as any medical conditions that you have. This will help ensure that the medication is safe and effective for you to use.

Atenolol is a beta-blocker medication that is primarily used to treat hypertension (high blood pressure), angina (chest pain), and certain types of heart rhythm disorders. It works by blocking the action of certain hormones in the body, such as adrenaline, on the heart and blood vessels. This helps to reduce the heart's workload, lower its rate and force of contractions, and improve blood flow.

Beta-blockers like atenolol are also sometimes used to prevent migraines or to treat symptoms of anxiety, such as rapid heartbeat or tremors. Atenolol is available in immediate-release and extended-release forms, and it is typically taken orally once or twice a day. As with any medication, atenolol can have side effects, including dizziness, fatigue, and gastrointestinal symptoms, and it may interact with other medications or medical conditions. It is important to use atenolol only under the supervision of a healthcare provider.

Renin is a medically recognized term and it is defined as:

"A protein (enzyme) that is produced and released by specialized cells (juxtaglomerular cells) in the kidney. Renin is a key component of the renin-angiotensin-aldosterone system (RAAS), which helps regulate blood pressure and fluid balance in the body.

When the kidney detects a decrease in blood pressure or a reduction in sodium levels, it releases renin into the bloodstream. Renin then acts on a protein called angiotensinogen, converting it to angiotensin I. Angiotensin-converting enzyme (ACE) subsequently converts angiotensin I to angiotensin II, which is a potent vasoconstrictor that narrows blood vessels and increases blood pressure.

Additionally, angiotensin II stimulates the adrenal glands to release aldosterone, a hormone that promotes sodium reabsorption in the kidneys and increases water retention, further raising blood pressure.

Therefore, renin plays a critical role in maintaining proper blood pressure and electrolyte balance in the body."

Sprague-Dawley rats are a strain of albino laboratory rats that are widely used in scientific research. They were first developed by researchers H.H. Sprague and R.C. Dawley in the early 20th century, and have since become one of the most commonly used rat strains in biomedical research due to their relatively large size, ease of handling, and consistent genetic background.

Sprague-Dawley rats are outbred, which means that they are genetically diverse and do not suffer from the same limitations as inbred strains, which can have reduced fertility and increased susceptibility to certain diseases. They are also characterized by their docile nature and low levels of aggression, making them easier to handle and study than some other rat strains.

These rats are used in a wide variety of research areas, including toxicology, pharmacology, nutrition, cancer, and behavioral studies. Because they are genetically diverse, Sprague-Dawley rats can be used to model a range of human diseases and conditions, making them an important tool in the development of new drugs and therapies.

Captopril is a medication that belongs to a class of drugs called ACE (angiotensin-converting enzyme) inhibitors. It works by blocking the action of a chemical in the body called angiotensin II, which causes blood vessels to narrow and release hormones that can increase blood pressure. By blocking the action of angiotensin II, captopril helps relax and widen blood vessels, which lowers blood pressure and improves blood flow.

Captopril is used to treat high blood pressure (hypertension), congestive heart failure, and to improve survival after a heart attack. It may also be used to protect the kidneys from damage due to diabetes or high blood pressure. The medication comes in the form of tablets that are taken by mouth, usually two to three times per day.

Common side effects of captopril include cough, dizziness, headache, and skin rash. More serious side effects may include allergic reactions, kidney problems, and changes in blood cell counts. It is important for patients taking captopril to follow their doctor's instructions carefully and report any unusual symptoms or side effects promptly.

A kidney, in medical terms, is one of two bean-shaped organs located in the lower back region of the body. They are essential for maintaining homeostasis within the body by performing several crucial functions such as:

1. Regulation of water and electrolyte balance: Kidneys help regulate the amount of water and various electrolytes like sodium, potassium, and calcium in the bloodstream to maintain a stable internal environment.

2. Excretion of waste products: They filter waste products from the blood, including urea (a byproduct of protein metabolism), creatinine (a breakdown product of muscle tissue), and other harmful substances that result from normal cellular functions or external sources like medications and toxins.

3. Endocrine function: Kidneys produce several hormones with important roles in the body, such as erythropoietin (stimulates red blood cell production), renin (regulates blood pressure), and calcitriol (activated form of vitamin D that helps regulate calcium homeostasis).

4. pH balance regulation: Kidneys maintain the proper acid-base balance in the body by excreting either hydrogen ions or bicarbonate ions, depending on whether the blood is too acidic or too alkaline.

5. Blood pressure control: The kidneys play a significant role in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), which constricts blood vessels and promotes sodium and water retention to increase blood volume and, consequently, blood pressure.

Anatomically, each kidney is approximately 10-12 cm long, 5-7 cm wide, and 3 cm thick, with a weight of about 120-170 grams. They are surrounded by a protective layer of fat and connected to the urinary system through the renal pelvis, ureters, bladder, and urethra.

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor, which is a type of medication used to treat various cardiovascular conditions. It works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in relaxation and widening of blood vessels, decreased blood pressure, and increased blood flow.

Lisinopril is primarily used to treat hypertension (high blood pressure), congestive heart failure, and to improve survival after a heart attack. It may also be used to protect the kidneys from damage due to diabetes or high blood pressure. Additionally, it has been shown to reduce proteinuria (excess protein in urine) in patients with diabetic nephropathy.

Common side effects of Lisinopril include dizziness, headache, fatigue, and cough. More serious side effects may include angioedema (rapid swelling of the face, lips, tongue, or throat), hyperkalemia (elevated potassium levels), and impaired kidney function.

It is important to follow the prescribing physician's instructions carefully when taking Lisinopril and to report any unusual symptoms promptly. Regular monitoring of blood pressure, kidney function, and electrolyte levels may be necessary during treatment with this medication.

SHR (Spontaneously Hypertensive Rats) are an inbred strain of rats that were originally developed through selective breeding for high blood pressure. They are widely used as a model to study hypertension and related cardiovascular diseases, as well as neurological disorders such as stroke and dementia.

Inbred strains of animals are created by mating genetically identical individuals (siblings or offspring) for many generations, resulting in a population that is highly homozygous at all genetic loci. This means that the animals within an inbred strain are essentially genetically identical to one another, which makes them useful for studying the effects of specific genes or environmental factors on disease processes.

SHR rats develop high blood pressure spontaneously, without any experimental manipulation, and show many features of human hypertension, such as increased vascular resistance, left ventricular hypertrophy, and renal dysfunction. They also exhibit a number of behavioral abnormalities, including hyperactivity, impulsivity, and cognitive deficits, which make them useful for studying the neurological consequences of hypertension and other cardiovascular diseases.

Overall, inbred SHR rats are an important tool in biomedical research, providing a valuable model for understanding the genetic and environmental factors that contribute to hypertension and related disorders.

"Wistar rats" are a strain of albino rats that are widely used in laboratory research. They were developed at the Wistar Institute in Philadelphia, USA, and were first introduced in 1906. Wistar rats are outbred, which means that they are genetically diverse and do not have a fixed set of genetic characteristics like inbred strains.

Wistar rats are commonly used as animal models in biomedical research because of their size, ease of handling, and relatively low cost. They are used in a wide range of research areas, including toxicology, pharmacology, nutrition, cancer, cardiovascular disease, and behavioral studies. Wistar rats are also used in safety testing of drugs, medical devices, and other products.

Wistar rats are typically larger than many other rat strains, with males weighing between 500-700 grams and females weighing between 250-350 grams. They have a lifespan of approximately 2-3 years. Wistar rats are also known for their docile and friendly nature, making them easy to handle and work with in the laboratory setting.

I'm sorry for any confusion, but "Pyridines" is not a medical term. It is a chemical term that refers to a class of organic compounds with the chemical structure of a six-membered ring containing one nitrogen atom and five carbon atoms (heterocyclic aromatic compound).

In a biological or medical context, pyridine derivatives can be found in various natural and synthetic substances. For example, some medications contain pyridine rings as part of their chemical structure. However, "Pyridines" itself is not a medical term or condition.

Proteinuria is a medical term that refers to the presence of excess proteins, particularly albumin, in the urine. Under normal circumstances, only small amounts of proteins should be found in the urine because the majority of proteins are too large to pass through the glomeruli, which are the filtering units of the kidneys.

However, when the glomeruli become damaged or diseased, they may allow larger molecules such as proteins to leak into the urine. Persistent proteinuria is often a sign of kidney disease and can indicate damage to the glomeruli. It is usually detected through a routine urinalysis and may be confirmed with further testing.

The severity of proteinuria can vary, and it can be a symptom of various underlying conditions such as diabetes, hypertension, glomerulonephritis, and other kidney diseases. Treatment for proteinuria depends on the underlying cause and may include medications to control blood pressure, manage diabetes, or reduce protein loss in the urine.

Left ventricular hypertrophy (LVH) is a medical condition in which the left ventricle of the heart undergoes an enlargement or thickening of its muscle wall. The left ventricle is the main pumping chamber of the heart that supplies oxygenated blood to the rest of the body.

In response to increased workload, such as hypertension (high blood pressure), aortic valve stenosis, or athletic training, the left ventricular muscle may thicken and enlarge. This process is called "hypertrophy." While some degree of hypertrophy can be adaptive in athletes, significant or excessive hypertrophy can lead to impaired relaxation and filling of the left ventricle during diastole, reduced pumping capacity, and decreased compliance of the chamber.

Left ventricular hypertrophy is often asymptomatic initially but can increase the risk of various cardiovascular complications such as heart failure, arrhythmias, myocardial infarction (heart attack), and sudden cardiac death over time. It is typically diagnosed through imaging techniques like echocardiography or cardiac MRI and confirmed by measuring the thickness of the left ventricular wall.

Angiotensins are a group of hormones that play a crucial role in the body's cardiovascular system, particularly in regulating blood pressure and fluid balance. The most well-known angiotensins are Angiotensin I, Angiotensin II, and Angiotensin-(1-7).

Angiotensinogen is a protein produced mainly by the liver. When the body requires an increase in blood pressure, renin (an enzyme produced by the kidneys) cleaves angiotensinogen to form Angiotensin I. Then, another enzyme called angiotensin-converting enzyme (ACE), primarily found in the lungs, converts Angiotensin I into Angiotensin II.

Angiotensin II is a potent vasoconstrictor, causing blood vessels to narrow and increase blood pressure. It also stimulates the release of aldosterone from the adrenal glands, which leads to increased sodium reabsorption in the kidneys, further raising blood pressure and promoting fluid retention.

Angiotensin-(1-7) is a more recently discovered member of the angiotensin family. It has opposing effects to Angiotensin II, acting as a vasodilator and counterbalancing some of the negative consequences of Angiotensin II's actions.

Medications called ACE inhibitors and ARBs (angiotensin receptor blockers) are commonly used in clinical practice to target the renin-angiotensin system, lowering blood pressure and protecting against organ damage in various cardiovascular conditions.

I am not aware of a specific medical definition for "1-Sarcosine-8-Isoleucine Angiotensin II." It is possible that this term is being used to describe an altered or modified form of the peptide hormone angiotensin II.

Angiotensin II is a powerful vasoconstrictor and plays a central role in the regulation of blood pressure and fluid balance. Its octapeptide structure consists of eight amino acids, with the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe.

Modifying this sequence by replacing one or more amino acids can result in altered biological activity. In this case, "1-Sarcosine-8-Isoleucine" suggests that the first amino acid (Aspartic Acid) has been replaced with Sarcosine (N-methylglycine), and the eighth amino acid (Phenylalanine) has been replaced with Isoleucine.

However, without further context or research, it is difficult to provide a precise medical definition for this term. If you are seeking information on a specific scientific study or application, please provide more details so that I can give a more informed response.

Vasoconstrictor agents are substances that cause the narrowing of blood vessels by constricting the smooth muscle in their walls. This leads to an increase in blood pressure and a decrease in blood flow. They work by activating the sympathetic nervous system, which triggers the release of neurotransmitters such as norepinephrine and epinephrine that bind to alpha-adrenergic receptors on the smooth muscle cells of the blood vessel walls, causing them to contract.

Vasoconstrictor agents are used medically for a variety of purposes, including:

* Treating hypotension (low blood pressure)
* Controlling bleeding during surgery or childbirth
* Relieving symptoms of nasal congestion in conditions such as the common cold or allergies

Examples of vasoconstrictor agents include phenylephrine, oxymetazoline, and epinephrine. It's important to note that prolonged use or excessive doses of vasoconstrictor agents can lead to rebound congestion and other adverse effects, so they should be used with caution and under the guidance of a healthcare professional.

The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.

Benzimidazoles are a class of heterocyclic compounds containing a benzene fused to a imidazole ring. They have a wide range of pharmacological activities and are used in the treatment of various diseases. Some of the benzimidazoles are used as antiparasitics, such as albendazole and mebendazole, which are effective against a variety of worm infestations. Other benzimidazoles have antifungal properties, such as thiabendazole and fuberidazole, and are used to treat fungal infections. Additionally, some benzimidazoles have been found to have anti-cancer properties and are being investigated for their potential use in cancer therapy.

Diabetic nephropathy is a kidney disease that occurs as a complication of diabetes. It is also known as diabetic kidney disease (DKD). This condition affects the ability of the kidneys to filter waste and excess fluids from the blood, leading to their accumulation in the body.

Diabetic nephropathy is caused by damage to the small blood vessels in the kidneys, which can occur over time due to high levels of glucose in the blood. This damage can lead to scarring and thickening of the kidney's filtering membranes, reducing their ability to function properly.

Symptoms of diabetic nephropathy may include proteinuria (the presence of protein in the urine), edema (swelling in the legs, ankles, or feet due to fluid retention), and hypertension (high blood pressure). Over time, if left untreated, diabetic nephropathy can progress to end-stage kidney disease, which requires dialysis or a kidney transplant.

Preventing or delaying the onset of diabetic nephropathy involves maintaining good control of blood sugar levels, keeping blood pressure under control, and making lifestyle changes such as quitting smoking, eating a healthy diet, and getting regular exercise. Regular monitoring of kidney function through urine tests and blood tests is also important for early detection and treatment of this condition.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Peptidyl-dipeptidase A is more commonly known as angiotensin-converting enzyme (ACE). It is a key enzyme in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance.

ACE is a membrane-bound enzyme found primarily in the lungs, but also in other tissues such as the heart, kidneys, and blood vessels. It plays a crucial role in converting the inactive decapeptide angiotensin I into the potent vasoconstrictor octapeptide angiotensin II, which constricts blood vessels and increases blood pressure.

ACE also degrades the peptide bradykinin, which is involved in the regulation of blood flow and vascular permeability. By breaking down bradykinin, ACE helps to counteract its vasodilatory effects, thereby maintaining blood pressure homeostasis.

Inhibitors of ACE are widely used as medications for the treatment of hypertension, heart failure, and diabetic kidney disease, among other conditions. These drugs work by blocking the action of ACE, leading to decreased levels of angiotensin II and increased levels of bradykinin, which results in vasodilation, reduced blood pressure, and improved cardiovascular function.

"DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ... "DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ... "DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ... "DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ...
Losartan, valsartan, candesartan, irbesartan, telmisartan and olmesartan all contain a biphenyl-methyl group. Losartan is ... a metabolite of losartan (MK954, DuP753) is more potent than losartan in blocking the angiotensin ll-induced responses in ... In 1995 losartan was approved for clinical use in the United States and since then six additional ARBs have been approved. ... Losartan has the least affinity. ARBs' affinity for the AT2 receptor is generally much lower (or around 10,000 times less) than ...
Ruth Wexler is an American industrial chemist best known as a co-discoverer of apixaban, a marketed anticoagulant; and losartan ...
"LOSARTAN- losartan potassium tablet, film coated". DailyMed. 2018-12-26. Retrieved 2019-02-06. "Drug Development and Drug ...
Research demonstrates that forasartan is also significantly less potent than losartan. Discovery and development of angiotensin ...
"ARB Recalls: Valsartan, Losartan and Irbesartan". U.S. Food and Drug Administration (FDA). 3 February 2020. Retrieved 12 ... Since July 2018, numerous recalls of losartan, valsartan and irbesartan drug products have caused marked shortages of these ... September 2001). "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy". ... "FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)". ...
These may include losartan, metoprolol, and pramipexole. Lofexidine is an agonist at the α-2A, 2B, and 2C adrenergic receptor ...
Losartan, a commonly used drug for the treatment of hypertension was shown to prevent epilepsy and facilitate BBB healing in ... Friedman A, Bar-Klein G, Serlin Y, Parmet Y, Heinemann U, Kaufer D (2014). "Should losartan be administered following brain ... Testing the potential of antiepileptogenic agents (e.g. losartan) or BBB healing drugs necessitates biomarkers for patients ...
Some drugs, e.g. Losartan, are also known to alter membrane viscosity. Another way to change membrane fluidity is to change the ...
Lin TH, Voon WC, Yen HW, Huang CH, Su HM, Lai WT, Sheu SH (April 2006). "Lercanidipine and losartan effects on blood pressure ...
... losartan) and Diovan (valsartan). A vast array of pharmaceuticals and agrochemicals are based on pyrimidines, such as Vitamin ...
Patti R, Sinha A, Sharma S, Yoon TS, Kupfer Y (May 2019). "Losartan-induced Severe Hepatic Injury: A Case Report and Literature ...
Angiotensin II receptor blockers - such as losartan and candesartan, often are tetrazoles. A well-known tetrazole is dimethyl ...
"Recalls of Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan". U.S. Food and Drug ... losartan, irbesartan and other "-sartan" drugs) contain nitrosamine impurities. "Irbesartan (Avapro) Use During Pregnancy". ...
Other specific common medications include Allopurinol, Enalapril, Losartan, insulin, and many more. Conditions that incriminate ...
... is not an angiotensin II receptor blocker (like losartan, for example). The Na-H transporter is also found in the ... antagonists like losartan, may lead to high levels of potassium in the blood, requiring frequent monitoring. Amiloride works by ...
In sought of a cure or a preventive means for this devastating process, they found that losartan, a commonly used drug for ... Understanding that clinical trials in possible antiepileptogenic agents (e.g. losartan) or BBB healing drugs necessitate ... 2014 Nov;71(11):1453-5. doi: 10.1001/jamaneurol PMID 25383774 Should losartan be administered following brain injury? Friedman ...
Therefore, losartan also holds promise for the treatment of Loeys-Dietz syndrome. In those patients in which losartan is not ... A large clinical trial sponsored by the National Institutes of Health is currently underway to explore the use of losartan to ... Previous research in laboratory mice has suggested that the angiotensin II receptor antagonist losartan, which appears to block ... with or without losartan, is sometimes prescribed to reduce the heart rate to prevent any extra pressure on the tissue of the ...
... on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115-9. doi:10.2133/dmpk.23.115. PMID ...
Gout may be worsened by thiazide diuretics, while losartan reduces serum urate. Kidney stones may be improved with the use of ... "Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout". ... azilsartan candesartan eprosartan irbesartan losartan olmesartan telmisartan valsartan Fimasartan In 2004, an article in the ...
"Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan ... the FDA issued notice of a sixth product recall of losartan by Torrent Pharmaceuticals when certain batches of losartan ... Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to ... "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP". Food and Drug ...
Losartan, Irbesartan, Valsartan, Olmesartan, and Azilsartan, are common ARBs that are clinically available. AT2R agonists cause ...
Three brands of losartan (a high blood pressure drug) are recalled due to unacceptable amounts of cancer-causing nitrosamine ... Khalik, Salma (28 March 2019). "HSA recalls three brands of high blood pressure drug losartan over cancer risk". The Straits ...
Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. The Journal of Clinical ...
Losartan (Cozaar) Methadone: Inhibits the metabolism of methadone and raises serum levels. Omeprazole (Losec, Prilosec) ...
April 2006). "Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome". Science. 312 (5770): ...
In some persons with loss-of-function mutations of URAT1, the uricosurics benzbromarone and losartan had no effect, suggesting ... Drugs with other primary uses, that have known uricosuric properties, include losartan, atorvastatin, and fenofibrate. Although ... Amlodipine Atorvastatin (lowers cholesterol) Fenofibrate (lowers triglycerides, raises HDL) Losartan Adrenocorticotropic ... "Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients". Am. J. Hypertens. ...
"Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis". Nephrology. 18 (9): ...
September 2002). "Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study". ...
Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. Nephron Exp ...
"DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ... "DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ... "DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ... "DailyMed - LOSARTAN POTASSIUM 25 MG- losartan potassium tablet, film coated LOSARTAN POTASSIUM 50 MG- losartan potassium tablet ...
Losartan Potassium Tablets Event Rate % Placebo Event Rate % Hazard Ratio (95% CI) Losartan Potassium Tablets Event Rate % ... The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 mg and do not change ... Coadministration of losartan and phenobarbital led to a reduction of about 20% in the AUC of losartan and that of its active ... Do not take losartan potassium tablets if you are allergic to any of the ingredients in losartan potassium tablets. See the end ...
The FDA has approved the first generic formulations of losartan potassium tablets, alone and in combination with ... Losartan tablets have been approved in 25-mg, 50-mg, and 100-mg doses; losartan/hydrocholorothiazide combination tablets will ... April 9, 2010 - The US Food and Drug Administration (FDA) has approved the first generic formulations of losartan potassium ... According to FDA officials, the generic losartan products will carry the same safety concerns as their brand counterparts, ...
Find information on Losartan (Cozaar) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications ... "Losartan." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. The Washington Manual, www.unboundmedicine.com/ ... washingtonmanual/view/Davis-Drug-Guide/109067/all/losartan. Vallerand AHA, Sanoski CAC, Quiring CC. Losartan. Daviss Drug ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Losartan. In Daviss Drug Guide (18th ed.). F.A. Davis Company. https ...
LOSARTAN POTASSIUM (UNII: 3ST302B24A) (LOSARTAN - UNII:JMS50MPO89) LOSARTAN POTASSIUM. 50 mg. HYDROCHLOROTHIAZIDE (UNII: ... LOSARTAN POTASSIUM (UNII: 3ST302B24A) (LOSARTAN - UNII:JMS50MPO89) LOSARTAN POTASSIUM. 100 mg. HYDROCHLOROTHIAZIDE (UNII: ... LOSARTAN POTASSIUM (UNII: 3ST302B24A) (LOSARTAN - UNII:JMS50MPO89) LOSARTAN POTASSIUM. 100 mg. HYDROCHLOROTHIAZIDE (UNII: ... Patients on monotherapy were titrated from losartan 50 mg to losartan 100 mg to losartan 150 mg, as needed. The primary ...
Explore,,Read: Recall Alert: Losartan potassium tablets recalled. This recall is the latest in the past few months. Since July ... Explore,,Read: Recall alert: Losartan potassium tablets recall expanded. The drugs contain too much N-nitroso-diethylamine ( ... Explore,,Read: Torrent Pharmaceuticals recalls Losartan blood pressure medicine due to unexpected impurity. Patients on the ... Macleods Pharmaceuticals Limited has voluntarily recalled the 100 mg/25 Losartan Potassium/Hydrochlorothiazide combination ...
Tagged With: Losartan, Losartan Lawsuits, Losartan Lawyers, Valsartan. Losartan Recalled Due to Nitroso-N-methyl-4-aminobutyric ... Tagged With: Losartan, Losartan Cancer, Losartan Cancer Lawsuits, Losartan Cancer Lawyers. Teva Expands Recall of Blood ... Tagged With: Losartan, Losartan Cancer Lawsuits, Losartan Cancer Lawyers, Losartan Lawyers. Update on Blood Pressure Medication ... Tagged With: Losartan, Losartan Cancer, Losartan Cancer Lawsuits, Losartan Cancer Lawyers. High Blood Pressure Medication ...
Bioaccumulation. Losartan has high potential for bioaccumulation.. Toxicity. Losartan has low chronic toxicity.. Risk. See the ... Sales of irbesartan are low in relation to candesartan and losartan. In 2018, over 18 times more losartan than irbesartan was ... if irbesartan was substituted for losartan or candesartan, the levels of losartan or candesartan in the environment would ... Persistence: Losartan has been found to degrade under natural light conditions however no data are available on metabolites. ...
Tagged With: Losartan Potassium Cancer Lawsuits, Losartan Potassium Cancer Lawyers, Losartan Potassium Recall ... Tagged With: Losartan Potassium Cancer Lawsuits, Losartan Potassium Cancer Lawyers, Losartan Potassium Recall ... Officials from the U.S. Federal Drug Administration issued the most recent recall of the drug losartan potassium and losartan ...
Losartan Potassium Losartan Potassium. Medicine Status PIL SPC XPIL Legal Category Active Ingredient(s) Company Cozaar 12.5mg, ... Losartan Potassium Organon Pharma (Ireland) Limited Cozaar COMP 50 mg/12.5 mg, 100 mg/12.5 mg, 100 mg/25 mg film-coated tablets ...
Contaminated losartan sees 3.2m tablets recalled in Taiwan. By Ben Hargreaves 03-Jan-2019. - Last updated on 03-Jan-2019 at 15: ... Related tags Taiwan losartan valsartan Taiwans Food and Drug Administration announced that Siu Guan will instigate a recall of ... The losartan used as an active ingredient in the medicine was found to contain N-Nitrosodiethylamine (NDEA), classified as a ...
b,Is losartan + amlodipine safe,/b, for treating hypertension in persons of 35-40 age group? ... Losartan (sold under various brand names such as Losacar) can be started at 50 mg once daily and increased to 100mg once daily ... Combination of losartan with amlodipine is irrational and hence is not permitted in any advanced country such as UK, Canada, ... Q: Is losartan + amlodipine safe for treating hypertension in persons of 35-40 age group? ...
CROI:Losartan Does Not Improve Inflammation or Fibrosis Markers in Older People on ART - Mark Mascolini (03/11/20). JV Baker, J ... Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease. "LIFE HIV Study" ...
Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets ... Losartan Potassium/ Hydrochlorothiazide combination tablets 100mg/25mg, 90 count bottles. BLM715A. Jul -2019. ... Losartan Potassium/Hydrochlorothiazide combination tablets are indicated to treat hypertension and hypertensive patients with ... Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg were distributed nationwide to Macleods wholesale ...
... is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. Due to the detection of an ... Losartan Potassium Tablets USP, 25 mg. CLO17006A. 90s. Nov 2019. HERITAGE Losartan Potassium Tablets USP, 50 mg. CLO17007A. ... Losartan Potassium Tablets USP, 50 mg. CLO17008A. 1000s. Nov 2019. HERITAGE Losartan Potassium Tablets USP, 50 mg. CLO17009A. ... Losartan Potassium Tablets USP, 50 mg. CLO17009B. 90s. Nov 2019. HERITAGE Losartan Potassium Tablets USP, 50 mg. CLO17010A. ...
... April 11, 2022. by test How to Get Rid of Brain Fog. Are you plagued by brain fog? If so, youre ...
Losartan/Hydrochlorothiazide Oral Tablet 50/12.5 mg, 100/12.5 mg, 100/25 mg. For high blood pressure. ... Losartan/Hydrochlorothiazide Oral Tablet 50/12.5 mg, 100/12.5 mg, 100/25 mg ...
To investigate the effect of losartan on vascular remodeling and transforming growth factor-beta and phosphoinositide 3-kinase/ ... They were randomly divided into losartan group, which was given losartan 20 mg/kg/d by gavage, model group, gavaged with the ... The diameter of aortic lumen in losartan group was reduced than that in model group, and the ratio of the thickness of the ... Losartan Regulates Transforming Growth Factor-Beta and Phosphoinositide 3-Kinase/Protein Kinase B Pathway Inhibits Vascular ...
Effects of Losartan Titrated to Losartan/Hydrochlorothiazide and Amlodipine on Left Ventricular Mass in Patients with Mild-to- ... Reduction of QT Dispersion by Losartan in Patients with Mild to Moderate Hypertension Subject Area: Cardiovascular System , ... QT dispersion, Arterial hypertension, Losartan, Angiotensin II antagonist, Amlodipine, Calcium antagonist, Hypertension ... Treatment with losartan significantly reduced LVM (from 311 ± 31 to 252 ± 16 g, mean ± SE; p , 0.01), cardiac mass index and ...
Uncover the best time to take Losartan and Amlodipine for optimal blood pressure management. Get expert advice tailored for ... When is the best time to take Losartan and Amlodipine?. The timing of Losartan and Amlodipine intake can vary based on ... The dosage of Losartan and Amlodipine may vary based on individual needs. Losartan can be taken once a day at a dose of 50mg to ... How can I determine the best treatment plan for Losartan and Amlodipine?. The best treatment plan for Losartan and Amlodipine ...
Losartan is a drug that helps prevent tightening of the blood vessels which can be used to treat high blood pressure, symptoms ... Losartan is sold under the name Cozaar. Losartan is used to treat high blood pressure, usually as a combination of medications ... Losartan Uses, Side Effects & Interactions. Losartan is a drug that helps prevent tightening of the blood vessels which can be ... Those under the age of 6 should not use Losartan.. Children with severe kidney issues may not be able to take Losartan as the ...
... Certain blood pressure drugs containing Losartan were recalled because they may contain a carcinogenic ... Losartan Recalls Due to NMBA. In September 2019, Torrent Pharma expanded a recall for Losartan after tests detected a cancer- ... What is Losartan?. Losartan is a generic medication that treats high blood pressure (hypertension) and helps protect the ... Losartan Recalls. April 2019 - Torrent Pharmaceuticals Ltd. announced a voluntary recall for Losartan Potassium Tablets USP and ...
Yes - my blood pressure was pretty much normal before I started taking Losartan - around 120 or so. After Losartan itd gone ... Its looking like losartan might be an effective way to ameliorate brain inflammation, boost cerebral blood flow, and regulate ... Ive since gone back on losartan at a higher dose (50mg/d) and combining this with florinef. Ive been getting periods of near ... Other than the blood pressure drop (which was the original intent of losartan) I dont get any other side effects. As for the ...
Losartan reduced strokes and new onset diabetes more than atenolol in essential hypertension ... Losartan reduced strokes and new onset diabetes more than atenolol in essential hypertension ...
... ... This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison ... The tablet combining L/HCTZ significantly reduced systolic and diastolic BP compared with the losartan monotherapy, and offered ... Thirty consecutive Japanese diabetic patients with hypertension were randomly assigned to group A, receiving losartan alone for ...
Losartan, hydroclorotiazide, , 1.32, 474.09, Hyzaar is used for treating high blood pressure. It may be used to decrease the ... LOSARTAN 50mg + HYDROCHLOROTHIAZIDE 12.5 mg is a combination of a drug that relaxes blood vessels and a diuretic. It is used to ... an unusual or allergic reaction to losartan, hydrochlorothiazide, sulfa drugs, other medicines, foods, dyes, or preservatives. ...
... Author(s): ... CONCLUSIONS: Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic ... The aim of our clinical trial is to assess the efficacy and safety of losartan versus atenolol in the prevention of progressive ... It will be a randomized, double blind trial with parallel assignment to atenolol versus losartan (50 mg per day in patients ...
... of the corpus cavernosum in aged rats and to evaluate the effects of the Angiotensin II type 1 receptor antagonist losartan on ... a losartan-treated AED (AED+Losartan) group. The treated group received losartan (30 mg/kg) once daily oral gavage for 4 weeks ... Restoration of Erectile Function by Suppression of Corporal Apoptosis and Oxidative Stress with Losartan in Aged Rats with ... After daily administration of losartan for four weeks, it could slightly restore erectile function and significantly attenuate ...
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in ...
... *This topic has 0 replies, 1 voice, and was last updated 1 month, ... FIND! Order Hyzaar Online Austria, Hyzaar losartan potasyum. No prescription is needed to shop for health at our online ...
  • April 9, 2010 - The US Food and Drug Administration (FDA) has approved the first generic formulations of losartan potassium tablets, alone and in combination with hydrochlorothiazide ( Cozaar and Hyzaar , Merck & Company, Inc), for the treatment of hypertension. (medscape.com)
  • The 100 mg/12.5 mg losartan/hydrochlorothiazide formulation will also be manufactured by several other companies, including Mylan Pharmaceuticals Inc, Roxane Laboratories Inc, and Torrent Pharmaceuticals Ltd. (medscape.com)
  • These highlights do not include all the information needed to use LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS safely and effectively. (nih.gov)
  • Hypersensitivity to any component of losartan potassium and hydrochlorothiazide tablets. (nih.gov)
  • Hypotension: Correct volume or salt depletion prior to administration of losartan potassium and hydrochlorothiazide tablets. (nih.gov)
  • Hepatic Impairment: Losartan potassium and hydrochlorothiazide tablets are not recommended for initial therapy, because the recommended starting dose is not available. (nih.gov)
  • Macleods Pharmaceuticals Limited has voluntarily recalled the 100 mg/25 Losartan Potassium/Hydrochlorothiazide combination tablets, the U.S. Food and Drug Administration announced . (springfieldnewssun.com)
  • WASHINGTON, D.C. - The U.S. Food and Drug Administration announced a safety recall for losartan potassium and losartan potassium/hydrochlorothiazide issued by the company that manufactures the drug Torrent Pharmaceuticals, Limited. (yourlawyer.com)
  • Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical ingredient made by Hetero Labs Limited. (fda.gov)
  • Macleods is recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg that contains NDEA above the interim acceptable daily intake levels released by the FDA. (fda.gov)
  • Losartan Potassium/Hydrochlorothiazide combination tablets are indicated to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy. (fda.gov)
  • Patients who are on Losartan Potassium/Hydrochlorothiazide combination tablets, USP should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment. (fda.gov)
  • Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg were distributed nationwide to Macleods wholesale distributor and retail customers. (fda.gov)
  • Twenty-eight adult patients with mild to moderate hypertension were randomly assigned to a double-blind treatment either with losartan 50 mg titrated to losartan 50 mg-hydrochlorothiazide 12.5 mg or amlodipine 5 mg titrated to amlodipine 10 mg. (karger.com)
  • In April 2019, Torrent Pharmaceuticals Ltd. announced a voluntary recall for Losartan Potassium Tablets USP and Losartan Potassium/Hydrochlorothiazide tablets, USP due to the detection of the impurity N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). (schmidtlaw.com)
  • April 2019 - Torrent Pharmaceuticals Ltd. announced a voluntary recall for Losartan Potassium Tablets USP and Losartan Potassium/Hydrochlorothiazide tablets. (schmidtlaw.com)
  • March 2019 - Torrent Pharmaceuticals Ltd. is recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, due to the detection of N-Methylnitrosobutyric acid (NMBA). (schmidtlaw.com)
  • November 2018 - Sandoz Inc. announced a voluntary recall for 100-mg/25-mg tablets of Hyzaar (Losartan and Hydrochlorothiazide). (schmidtlaw.com)
  • Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. (druglib.com)
  • This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension. (druglib.com)
  • LOSARTAN 50mg + HYDROCHLOROTHIAZIDE 12.5 mg is a combination of a drug that relaxes blood vessels and a diuretic. (canadianpharm.org)
  • Losartan may increase the hypotensive activities of Hydrochlorothiazide. (druginteractionchecker.com)
  • Drug1 (rxcui = 979464, name = Hydrochlorothiazide 12.5 MG / Losartan Potassium 100 MG Oral Tablet, tty = SCD). (druginteractionchecker.com)
  • Drug1 is resolved to Hydrochlorothiazide, Drug2 is resolved to Losartan and interaction asserted in DrugBank between Hydrochlorothiazide and Losartan. (druginteractionchecker.com)
  • This product contains two medications: losartan and hydrochlorothiazide. (healthwarehouse.com)
  • Read the Patient Information Leaflet if available from your pharmacist before you start taking losartan/hydrochlorothiazide and each time you get a refill. (healthwarehouse.com)
  • If you also take certain drugs to lower your cholesterol (bile acid-binding resins such as cholestyramine or colestipol), take losartan/hydrochlorothiazide at least 4 hours before or at least 4 to 6 hours after these medications. (healthwarehouse.com)
  • Losartan, sold under the brand name Cozaar among others, is a medication used to treat high blood pressure (hypertension). (wikipedia.org)
  • Fass environmental information for Cozaar (losartan) from MSD (downloaded 2021-06-28). (janusinfo.se)
  • Losartan is sold under the name Cozaar . (md-health.com)
  • Generic Cozaar has active ingredient(s) Losartan. (schickersunichem.co.nz)
  • Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level due to the detection of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer) that is above the US Food & Drug Administration's interim acceptable exposure limit of 9.82 ppm. (fda.gov)
  • Losartan (sold under various brand names such as Losacar) can be started at 50 mg once daily and increased to 100mg once daily, if necessary. (ndtv.com)
  • Losartan is typically taken once a day, with a recommended dosage of 50mg to 100mg for high blood pressure or kidney protection. (tagvault.org)
  • Losartan (100mg): R$ 36,198. (bvs.br)
  • Comparative assessment of environmental risk when using angiotensin II antagonists candesartan, losartan, valsartan, irbesartan, eprosartan and telmisartan from a Swedish perspective (Report Goodpoint 2019). (janusinfo.se)
  • However, growth studies (28-32 days) of fish for four of the substances (candesartan, losartan, valsartan, irbesartan) show low toxicity, but mechanism-based efficacy data are completely lacking for all. (janusinfo.se)
  • If patients take Losartan, Valsartan, or Irbesartan products, they should check the list periodically, as information may change. (schmidtlaw.com)
  • Examples of ARBs include losartan and valsartan. (medscape.com)
  • In September 2019, Torrent Pharma expanded a recall for Losartan after tests detected a cancer-causing impurity called NMBA. (schmidtlaw.com)
  • In April 2019, a recall was issued for 44 lots of Losartan potassium tablets manufactured by Teva Pharmaceuticals and labeled as Golden State Medical Supply due to the detection of NMBA. (schmidtlaw.com)
  • March 2019 - Another 87 lots of Losartan medications were recalled after the FDA detected a 3rd type of carcinogen called N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) at dangerous levels. (schmidtlaw.com)
  • March 2019 - Camber Pharmaceuticals Inc. recalled 87 lots of Losartan because it may contain a cancer-causing impurity. (schmidtlaw.com)
  • January 2019 - Torrent Pharmaceuticals announced an expanded recall for Losartan Potassium Tablets because they contain N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA. (schmidtlaw.com)
  • Losartan is used for hypertension, including in people with left ventricular hypertrophy (enlarged heart muscle), and kidney dysfunction among type II diabetics. (wikipedia.org)
  • Cite this: FDA Approves First Generic Formulations of Losartan for Hypertension - Medscape - Apr 09, 2010. (medscape.com)
  • Is losartan + amlodipine safe for treating hypertension in persons of 35-40 age group? (ndtv.com)
  • Losartan Potassium is indicated for the treatment of hypertension, hypertensive patients with left ventricular hypertrophy, nephropathy in Type 2 diabetic patients and is packaged in 90-count and 1000-count bottles. (fda.gov)
  • Losartan significantly reduced QTd after 16 weeks of treatment in patients with mild to moderate hypertension. (karger.com)
  • Losartan is a generic medication that treats high blood pressure (hypertension) and helps protect the kidneys from damage due to diabetes (nephropathy). (schmidtlaw.com)
  • Thirty consecutive Japanese diabetic patients with hypertension were randomly assigned to group A, receiving losartan alone for the first 3 months, then L/HCTZ for the next 3 months, or group B, receiving L/HCTZ for the first 3 months, then losartan alone for the next 3 months. (druglib.com)
  • Losartan may also be taken by adults who have type 2 diabetes along with hypertension and protein in the urine ( proteinuria ). (rxhealthmed.ca)
  • Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. (mlivehosted.com)
  • Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (mlivehosted.com)
  • Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. (mlivehosted.com)
  • Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-ß, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. (bvsalud.org)
  • With regard to the medications, Atorvastatin , Losartan and Captopril were administered more in patients (groups 1, 2 and 3) than the patients without hypertension and CAD. (bvsalud.org)
  • Losartan, widely used to treat arterial hypertension in Brazil, was not protected by patents in either country and could be imported into either. (who.int)
  • Genetic sequencing tests confirmed losartan and hydrochlorothizide were prescribed to be taken infection with a rabies virus variant associated with tricolored orally for hypertension, but the patient was unable to swallow bats. (cdc.gov)
  • I've since gone back on losartan at a higher dose (50mg/d) and combining this with florinef. (dinet.org)
  • The tablet combining L/HCTZ significantly reduced systolic and diastolic BP compared with the losartan monotherapy, and offered benefits similar to losartan monotherapy for albuminuria, arterial stiffness assessed by the CAVI and AI, and metabolic effects. (druglib.com)
  • Drug2 (rxcui = 979480, name = Losartan Potassium 100 MG Oral Tablet, tty = SCD). (druginteractionchecker.com)
  • Each white-to-off-white, oval-shaped, film-coated tablet, debossed with 'J' on one side and '25' on the other, contains 25 mg losartan as losartan potassium. (rxhealthmed.ca)
  • Treatment usually starts with 50 mg losartan (one tablet Losartan 50 mg) once a day. (lynchspharmacy.com)
  • Generally, the dose should be increased weekly step-by-step (i.e. 12.5 mg daily during the first week, 25 mg daily during the second week, 50 mg daily during the third week) up to the usual maintenance dose of 50 mg losartan (one tablet Losartan 50 mg) once daily, according to your condition. (lynchspharmacy.com)
  • To study the effects of losartan in comparison to amlodipine on QTd in mildly to moderately hypertensive patients, and to assess correlations of reduced QTd with echocardiographic left ventricular mass (LVM). (karger.com)
  • Common side effects of Losartan include dizziness, sleepiness, and palpitations. (tagvault.org)
  • The full effects of losartan are usually seen within 3 to 6 weeks after treatment has started. (rxhealthmed.ca)
  • Losartan potassium is available as tablets for oral administration containing either 25 mg, 50 mg or 100 mg of losartan potassium and the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, pregelatinized starch, talc and titanium dioxide. (nih.gov)
  • PORTLAND, Ore. - Oregonlive.com recently examined the most current list of losartan blood pressure medications recalled by the companies that make the drug. (yourlawyer.com)
  • Losartan and Amlodipine are commonly prescribed medications for the treatment of high blood pressure. (tagvault.org)
  • While Losartan and Amlodipine are effective medications for managing high blood pressure, it is important to be aware of their potential side effects and take necessary precautions. (tagvault.org)
  • Additionally, certain medications may interact with Losartan and Amlodipine, leading to adverse effects or reducing their effectiveness. (tagvault.org)
  • Losartan is used to treat high blood pressure, usually as a combination of medications and treatments to help reduce the likelihood of heart attack or stroke. (md-health.com)
  • A small amount of blood pressure medications containing Losartan have been linked to a possible risk of cancer due to a toxic chemical impurity that was left over from the drug's manufacturing process. (schmidtlaw.com)
  • Losartan belongs to a family of medications known as angiotensin II receptor blockers . (rxhealthmed.ca)
  • Electrolyte imbalances may occur in people with kidney problems who take losartan. (wikipedia.org)
  • The best time to take Losartan and Amlodipine may vary based on individual needs and health conditions. (tagvault.org)
  • It is generally recommended to take Losartan initially before bedtime to minimize potential dizziness. (tagvault.org)
  • Children with severe kidney issues may not be able to take Losartan as the medication cannot be cleared from their system efficiently. (md-health.com)
  • Is losartan plus amlodipine combination safe? (ndtv.com)
  • Home » Frequently asked Questions on Health » Is losartan plus amlodipine combination safe? (ndtv.com)
  • Combination of losartan with amlodipine is irrational and hence is not permitted in any advanced country such as UK, Canada, Australia, etc. (ndtv.com)
  • Systolic and diastolic blood pressure were significantly reduced in the losartan and amlodipine groups. (karger.com)
  • In this article, we will explore the optimal dosing schedule for Losartan and Amlodipine , as well as the timing of their intake. (tagvault.org)
  • Regular monitoring and communication with your healthcare provider are essential for effective blood pressure management with Losartan and Amlodipine. (tagvault.org)
  • When it comes to taking Losartan and Amlodipine, it is essential to follow the recommended dosage and administration guidelines for optimal results. (tagvault.org)
  • Both Losartan and Amlodipine should be taken consistently and at the same time every day for optimal effectiveness. (tagvault.org)
  • While Losartan is often taken once daily, Amlodipine can also be taken at any time of the day. (tagvault.org)
  • While Losartan and Amlodipine are generally safe and well-tolerated, it's important to be aware of potential side effects and take necessary precautions. (tagvault.org)
  • Like any medication, Losartan and Amlodipine may cause side effects in some individuals. (tagvault.org)
  • Additionally, there may be other uncommon or rare side effects associated with Losartan and Amlodipine. (tagvault.org)
  • When taking Losartan and Amlodipine, there are certain precautions you should keep in mind to optimize your safety and the effectiveness of your treatment. (tagvault.org)
  • As with other angiotensin receptor blockers, losartan may injure the liver, although this effect appears to be rare. (wikipedia.org)
  • The decreases in systolic and diastolic blood pressure (BP) during treatment with L/HCTZ were significantly greater than in treatment with losartan alone. (druglib.com)
  • In October 2014, the U.S. Food and Drug Administration (FDA) issued a black box warning that losartan can cause fetal toxicity, and should be discontinued as soon as pregnancy is detected. (wikipedia.org)
  • When pregnancy is detected, discontinue losartan potassium tablets as soon as possible. (nih.gov)
  • losartan/hydrocholorothiazide combination tablets will be available in strength of 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg (Teva Pharmaceuticals, USA). (medscape.com)
  • In 2018, over 18 times more losartan than irbesartan was prescribed and just over 18 times more candesartan than irbesartan in Sweden (in DDD count, excluding combination preparation). (janusinfo.se)
  • to study the clinical and pharmacological aspects of angiotensin converting enzyme inhibitor lisinopril, angiotensin II receptor antagonist losartan and their combination in the treatment of chronic heart failure of II-IV functional classes. (cnaa.md)
  • monitoring the safety of complex therapy with losartan and lisinopril and their combination of patients with CHF of ischemic origin. (cnaa.md)
  • The given research has allowed to obtain new data on the evolution of clinical picture, hemodynamic and morpho-functional parameters of the heart of patients with CHF FC II-IV of ischemic origin to treatment with losartan, lisinopril and their combination. (cnaa.md)
  • Individualized pharmacological schemes of treatment of patients with CHF of ischemic origin with inclusion of lisinopril, losartan or their combination on basis of the complex study of the efficacy (clinical manifestations, morphofunctional and hemodynamic parameters of the heart, tolerance during pfysical efforts and quality of life) and safety of the treatment. (cnaa.md)
  • Losartan may be used alone or in combination with a diuretic (water pill). (rxhealthmed.ca)
  • Lithium containing medicines should not be taken in combination with losartan without close supervision by your doctor. (lynchspharmacy.com)
  • The dosage of Losartan may vary depending on the specific health condition being treated. (tagvault.org)
  • Losartan can also lower the risk of strokes in patients with an enlarged heart. (schmidtlaw.com)
  • Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. (druglib.com)
  • Recent trials have indicated the use of losartan (a transforming growth factor beta inhibitor) in these patients prevents aortic root enlargement. (druglib.com)
  • The aim of our clinical trial is to assess the efficacy and safety of losartan versus atenolol in the prevention of progressive dilation of the aorta in patients with Marfan syndrome. (druglib.com)
  • It will be a randomized, double blind trial with parallel assignment to atenolol versus losartan (50 mg per day in patients below 50 kg and 100 mg per day in patients over 50 kg). (druglib.com)
  • Scientific problem addressed is to increase the effectiveness and safety of drug therapy in patients with CHF FC II-IV of ischemic origin using lisinopril, losartan or their association by optimization and individualization of regimens, rational use of preparations studied depending on their pharmacological properties and functional features of the patient. (cnaa.md)
  • In some patients the dose may later be increased to 100 mg losartan (two tablets Losartan 50 mg) once daily. (lynchspharmacy.com)
  • The recommended starting dose in patients who weigh between 20 and 50 kg is 0.7 mg of losartan per kg of body weight administered once a day (up to 25 mg of Losartan). (lynchspharmacy.com)
  • RÉSUMÉ Nous avions l'objectif d'étudier la prévalence des effets secondaires causés par les statines chez des patients iraniens admis dans un hôpital spécialisé en cardiologie et sous traitement par statines avant leur hospitalisation. (who.int)
  • Sales of irbesartan are low in relation to candesartan and losartan. (janusinfo.se)
  • Therefore, if irbesartan was substituted for losartan or candesartan, the levels of losartan or candesartan in the environment would probably only increase by about 6% on average and therefore increase the environmental risk for these marginally, but it would eliminate the environmental risk with irbesartan. (janusinfo.se)
  • An exchange of irbesartan with either losartan or candesartan may be justified, primarily based on the fact that the environmental exposure to losartan or candesartan would increase only marginally. (janusinfo.se)
  • In these cases, losartan is used to protect the kidneys from further damage due to diabetes. (rxhealthmed.ca)
  • One study demonstrated losartan was superior to atenolol in the primary prevention of adverse cardiovascular events (myocardial infarction or stroke), with a reduction in cardiovascular morbidity and mortality for a comparable reduction in blood pressure. (wikipedia.org)
  • CONCLUSIONS: Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study. (druglib.com)
  • Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. (cdc.gov)
  • UNITED STATES - Teva Pharmaceuticals has pulled several lots of Losartan off the market due to contamination with a probable carcinogenic substance. (yourlawyer.com)
  • Teva Pharmaceuticals announced a recall for Losartan that was sold by Golden State Medical Supply. (schmidtlaw.com)
  • December 2018 - Torrent Pharmaceuticals recalled 2 lots of Losartan due to NDEA. (schmidtlaw.com)
  • Losartan metabolites have been identified in human plasma and urine. (nih.gov)
  • In vitro studies indicate that cytochrome P450 2C9 and 3A4 are involved in the biotransformation of losartan to its metabolites. (nih.gov)
  • Persistence: 'Losartan has been found to degrade under natural light conditions however no data are available on metabolites. (janusinfo.se)
  • ACE-inhibitor enalapril plus ATII receptor antagonist losartan can reduce proteinuria. (lu.se)
  • 2023. https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/109067/all/losartan. (unboundmedicine.com)
  • In this population, losartan potassium reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation). (mlivehosted.com)
  • WASHINGTON, D.C. - Legacy Pharmaceutical Packing, the packing company for losartan high blood pressure medication, along with the U.S. Food and Drug Administration announced another recall for the drug because the pill contained a possible carcinogenic substance according to the U.S.A Today. (yourlawyer.com)
  • Losartan is a drug that helps prevent tightening of the blood vessels which can be used to treat high blood pressure, symptoms of diabetes or kidney conditions. (md-health.com)
  • Although evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (due to both efficacy and cost), an angiotensin II receptor antagonist such as losartan is recommended as first-line treatment in people under the age of 55 who cannot tolerate an ACE inhibitor. (wikipedia.org)
  • In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT1 receptor. (nih.gov)
  • The active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, non-competitive inhibitor of the AT1 receptor. (nih.gov)
  • If your heart failure has been stabilised with an ACE inhibitor you should not be switched to losartan. (lynchspharmacy.com)
  • Minimal conversion of losartan to the active metabolite (less than 1% of the dose compared to 14% of the dose in normal subjects) was seen in about one percent of individuals studied. (nih.gov)
  • The usual recommended dose of losartan for adults is 50 mg or 100 mg once daily. (rxhealthmed.ca)
  • The dose may later be increased to 100 mg losartan (two tablets Losartan 50 mg) once daily depending on your blood pressure response. (lynchspharmacy.com)
  • Losartan has protective effect on aortic wall of rats with aortic dissection, and the mechanism may be through inhibiting transforming growth factor-beta 1 pathway, which activates downstream phosphoinositide 3-kinase/protein kinase B pathway related proteins, and then inhibits the expansion and progression of aortic dissection. (ijpsonline.com)
  • The most common adverse effects for losartan in adults are upper respiratory infections, dizziness, and back pain. (wikipedia.org)
  • Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt. (nih.gov)
  • This led to the examinations of medicines produced using other 'sartan' medicines, such as losartan. (outsourcing-pharma.com)
  • Losartan belongs to a class of medicines known as angiotensin II receptor antagonists. (lynchspharmacy.com)
  • non-steroidal anti-inflammatory drugs such as indomethacin, including cox-2-inhibitors (medicines that reduce inflammation, and can be used to help relieve pain) as they may reduce the blood lowering effect of losartan. (lynchspharmacy.com)
  • Like all medicines, Losartan can cause side effects, although not everybody gets them. (lynchspharmacy.com)
  • Losartan may have adverse interactions with phenobarbital, rifampin, or fluconazole, possibly inhibiting its blood pressure-lowering effects. (wikipedia.org)
  • It is converted, in part, to an active carboxylic acid metabolite that is responsible for most of the angiotensin II receptor antagonism that follows losartan treatment. (nih.gov)
  • If you begin to suffer from dizziness, fast or slow heartbeat or fainting you may be suffering from an overdose of Losartan . (md-health.com)
  • WASHINGTON, D.C. - The Food and Drug Administration said that the recall of Losartan drugs must be expanded after detection of the carcinogen NMBA. (yourlawyer.com)
  • It's looking like losartan might be an effective way to ameliorate brain inflammation, boost cerebral blood flow, and regulate autonomic activity. (dinet.org)
  • These articles don't discuss losartan (or even Angiotensin II) but they do have some very interesting info on the current state of research on brain inflammation and the role it may play in a lot of diseases. (dinet.org)
  • According to the results it seems that Atorvastatin , Losartan and Captopril have reduced inflammation in in vivo conditions via downregulation of IL-6 and upregulation of TGF-ß. (bvsalud.org)
  • The risk or severity of adverse effects can be increased when Losartan is combined with Atorvastatin. (druginteractionchecker.com)
  • The maximal effects on blood pressure usually occur within 3-6 weeks of starting losartan. (wikipedia.org)
  • Losartan is a widely used blood pressure medicine. (yourlawyer.com)
  • Losartan is an angiotensin II receptor blocker (ARB) which is used to relax the blood vessels in order to help lower blood pressure in the body. (md-health.com)
  • Certain blood pressure drugs containing Losartan were recalled because they may contain a carcinogenic impurity that could potentially raise a user's risk of cancer. (schmidtlaw.com)
  • Yes - my blood pressure was pretty much normal before I started taking Losartan - around 120 or so. (dinet.org)
  • Other than the blood pressure drop (which was the original intent of losartan) I don't get any other side effects. (dinet.org)
  • Losartan blocks the action of angiotensin II, resulting in the relaxation of the blood vessels. (rxhealthmed.ca)
  • Losartan tablets are used in relaxing blood vessels, by doing this patient's blood pressure can be controlled. (cardiodiabeticcompanies.in)
  • Losartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. (lynchspharmacy.com)
  • I think that explains why the omitted phrase recognising the similarites Losartan brand For Order our societies is, for story, and I think it ended her class solved it correctly, my own flesh and blood, an indelible testament communities and their countries economies. (season2seasonconstruction.com)
  • Losartan is an angiotensin receptor blocker and works by relaxing blood vessels so that blood can flow more easily. (healthwarehouse.com)
  • They were randomly divided into losartan group, which was given losartan 20 mg/kg/d by gavage, model group, gavaged with the same amount of normal saline, and 10 normal newborn rats were given the same amount of normal saline by gavage as normal group. (ijpsonline.com)
  • Restoration of Erectile Function by Suppression of Corporal Apoptosis and Oxidative Stress with Losartan in Aged Rats with Erectile Dysfunction. (physiciansweekly.com)
  • Legacy Pharmaceuticals also expanded its recall to include 1 additional lot of Losartan. (schmidtlaw.com)
  • ultram (losartan) - Also availble in 50 mg pills. (3dup.net)

No images available that match "losartan"